These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

429 related items for PubMed ID: 17478733

  • 1. Distinct architecture of lymphatic vessels induced by chimeric vascular endothelial growth factor-C/vascular endothelial growth factor heparin-binding domain fusion proteins.
    Tammela T, He Y, Lyytikkä J, Jeltsch M, Markkanen J, Pajusola K, Ylä-Herttuala S, Alitalo K.
    Circ Res; 2007 May 25; 100(10):1468-75. PubMed ID: 17478733
    [Abstract] [Full Text] [Related]

  • 2. Enhanced capillary formation stimulated by a chimeric vascular endothelial growth factor/vascular endothelial growth factor-C silk domain fusion protein.
    Keskitalo S, Tammela T, Lyytikka J, Karpanen T, Jeltsch M, Markkanen J, Yla-Herttuala S, Alitalo K.
    Circ Res; 2007 May 25; 100(10):1460-7. PubMed ID: 17478734
    [Abstract] [Full Text] [Related]

  • 3. Comparative evaluation of FGF-2-, VEGF-A-, and VEGF-C-induced angiogenesis, lymphangiogenesis, vascular fenestrations, and permeability.
    Cao R, Eriksson A, Kubo H, Alitalo K, Cao Y, Thyberg J.
    Circ Res; 2004 Mar 19; 94(5):664-70. PubMed ID: 14739162
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Tumor-induced activation of lymphatic endothelial cells via vascular endothelial growth factor receptor-2 is critical for prostate cancer lymphatic metastasis.
    Zeng Y, Opeskin K, Goad J, Williams ED.
    Cancer Res; 2006 Oct 01; 66(19):9566-75. PubMed ID: 17018613
    [Abstract] [Full Text] [Related]

  • 8. Chimeric VEGF-E(NZ7)/PlGF promotes angiogenesis via VEGFR-2 without significant enhancement of vascular permeability and inflammation.
    Zheng Y, Murakami M, Takahashi H, Yamauchi M, Kiba A, Yamaguchi S, Yabana N, Alitalo K, Shibuya M.
    Arterioscler Thromb Vasc Biol; 2006 Sep 01; 26(9):2019-26. PubMed ID: 16794222
    [Abstract] [Full Text] [Related]

  • 9. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses.
    Rissanen TT, Markkanen JE, Gruchala M, Heikura T, Puranen A, Kettunen MI, Kholová I, Kauppinen RA, Achen MG, Stacker SA, Alitalo K, Ylä-Herttuala S.
    Circ Res; 2003 May 30; 92(10):1098-106. PubMed ID: 12714562
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. An engineered heparin-binding form of VEGF-E (hbVEGF-E). Biological effects in vitro and mobilizatiion of precursor cells.
    Heil M, Mitnacht-Krauss R, Issbrücker K, van den Heuvel J, Dehio C, Schaper W, Clauss M, Weich HA.
    Angiogenesis; 2003 May 30; 6(3):201-11. PubMed ID: 15041796
    [Abstract] [Full Text] [Related]

  • 12. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice.
    Veikkola T, Jussila L, Makinen T, Karpanen T, Jeltsch M, Petrova TV, Kubo H, Thurston G, McDonald DM, Achen MG, Stacker SA, Alitalo K.
    EMBO J; 2001 Mar 15; 20(6):1223-31. PubMed ID: 11250889
    [Abstract] [Full Text] [Related]

  • 13. Suppression of tumor growth and metastasis by simultaneously blocking vascular endothelial growth factor (VEGF)-A and VEGF-C with a receptor-immunoglobulin fusion protein.
    Zhang D, Li B, Shi J, Zhao L, Zhang X, Wang C, Hou S, Qian W, Kou G, Wang H, Guo Y.
    Cancer Res; 2010 Mar 15; 70(6):2495-503. PubMed ID: 20197464
    [Abstract] [Full Text] [Related]

  • 14. Expression of VEGFR-3 and 5'-nase in regenerating lymphatic vessels of the cutaneous wound healing.
    Ji RC, Miura M, Qu P, Kato S.
    Microsc Res Tech; 2004 Jun 15; 64(3):279-86. PubMed ID: 15452895
    [Abstract] [Full Text] [Related]

  • 15. Adenoviral VEGF-C overexpression induces blood vessel enlargement, tortuosity, and leakiness but no sprouting angiogenesis in the skin or mucous membranes.
    Saaristo A, Veikkola T, Enholm B, Hytönen M, Arola J, Pajusola K, Turunen P, Jeltsch M, Karkkainen MJ, Kerjaschki D, Bueler H, Ylä-Herttuala S, Alitalo K.
    FASEB J; 2002 Jul 15; 16(9):1041-9. PubMed ID: 12087065
    [Abstract] [Full Text] [Related]

  • 16. Vascular endothelial growth factor-a promotes peritumoral lymphangiogenesis and lymphatic metastasis.
    Björndahl MA, Cao R, Burton JB, Brakenhielm E, Religa P, Galter D, Wu L, Cao Y.
    Cancer Res; 2005 Oct 15; 65(20):9261-8. PubMed ID: 16230387
    [Abstract] [Full Text] [Related]

  • 17. Vascular endothelial growth factor-C and C-C chemokine receptor 7 in tumor cell-lymphatic cross-talk promote invasive phenotype.
    Issa A, Le TX, Shoushtari AN, Shields JD, Swartz MA.
    Cancer Res; 2009 Jan 01; 69(1):349-57. PubMed ID: 19118020
    [Abstract] [Full Text] [Related]

  • 18. Profound but dysfunctional lymphangiogenesis via vascular endothelial growth factor ligands from CD11b+ macrophages in advanced ovarian cancer.
    Jeon BH, Jang C, Han J, Kataru RP, Piao L, Jung K, Cha HJ, Schwendener RA, Jang KY, Kim KS, Alitalo K, Koh GY.
    Cancer Res; 2008 Feb 15; 68(4):1100-9. PubMed ID: 18281485
    [Abstract] [Full Text] [Related]

  • 19. Immunohistochemical analysis of VEGF-C/VEGFR-3 system and lymphatic vessel extent in normal and adenomatous human pituitary tissues.
    Onofri C, Losa M, Uhl E, Stalla GK, Renner U.
    Exp Clin Endocrinol Diabetes; 2008 Mar 15; 116(3):152-7. PubMed ID: 18205092
    [Abstract] [Full Text] [Related]

  • 20. Lymphangiogenesis and its relationship with lymphatic metastasis and prognosis in malignant melanoma.
    Liu B, Ma J, Wang X, Su F, Li X, Yang S, Ma W, Zhang Y.
    Anat Rec (Hoboken); 2008 Oct 15; 291(10):1227-35. PubMed ID: 18561194
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.